Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.

Literature DB >> 23212393

Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.

Lafaine M Grant¹, David E Kleiner, Hari S Conjeevaram, Raj Vuppalanchi, William M Lee.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 23212393 PMCID： PMC3826911 DOI： 10.1007/s10620-012-2493-9

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

× No keyword cloud information.

17 in total

Review 1. Criteria of drug-induced liver disorders. Report of an international consensus meeting.

Authors: C Bénichou
Journal: J Hepatol Date: 1990-09 Impact factor: 25.083

2. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).

Authors: Silvia Scoccianti; Stefano Maria Magrini; Umberto Ricardi; Beatrice Detti; Michela Buglione; Guido Sotti; Marco Krengli; Sergio Maluta; Salvatore Parisi; Filippo Bertoni; Cristina Mantovani; Vincenzo Tombolini; Costantino De Renzis; Marco Lioce; Lucia Fatigante; Vincenzo Fusco; Paolo Muto; Franco Berti; Giovanni Rubino; Samantha Cipressi; Laura Fariselli; Marco Lupattelli; Riccardo Santoni; Luigi Pirtoli; Giampaolo Biti
Journal: Neurosurgery Date: 2010-08 Impact factor: 4.654

3. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.

Authors: L J Fairbairn; N Chinnasamy; L S Lashford; D Chinnasamy; J A Rafferty
Journal: Cancer Gene Ther Date: 2000-02 Impact factor: 5.987

4. Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis.

Authors: Tom Mikkelsen; Joe Anderson; Thomas J Doyle; David Croteau; Rita Avedissian; Sam Ryu; Lonni Schultz
Journal: J Neurooncol Date: 2010-04-30 Impact factor: 4.130

5. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

Authors: M R Middleton; J J Grob; N Aaronson; G Fierlbeck; W Tilgen; S Seiter; M Gore; S Aamdal; J Cebon; A Coates; B Dreno; M Henz; D Schadendorf; A Kapp; J Weiss; U Fraass; P Statkevich; M Muller; N Thatcher
Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544

Review 6. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Authors: S S Agarwala; J M Kirkwood
Journal: Oncologist Date: 2000

7. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors: W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544

8. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.

Authors: Don C Rockey; Leonard B Seeff; James Rochon; James Freston; Naga Chalasani; Maurizio Bonacini; Robert J Fontana; Paul H Hayashi
Journal: Hepatology Date: 2010-06 Impact factor: 17.425

Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.

Review 1. Criteria of drug-induced liver disorders. Report of an international consensus meeting.

2. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).

3. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.

4. Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis.

5. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

Review 6. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

7. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

8. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.

9. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.

10. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

1. Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.

Review 2. Drug-induced Liver Injury: The Hepatic Pathologist's Approach.

3. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.

Review 4. Recent Advances in the Histopathology of Drug-Induced Liver Injury.

5. Nationwide longitudinal analysis of acute liver failure in taiwan.

6. Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo.